We're committed to running our business responsibly and to making GSK more responsive, more flexible and more open to the expectations of society. We're also determined to deliver on our promises to make GSK more transparent and to seek new solutions and innovative partnerships to make our medicines and vaccines more accessible to those who need them most.
Today we published our 2009 Corporate Responsibility (CR) Report. The CR Report covers the progress made on new standards of clinical transparency and steps to improve global public health. We've also announced the principles of GSK's flexible pricing strategy which will increase access to medicines and vaccines for patients in middle income countries.
And, for the first time, we've provided examples of how we are implementing our 2009 pledge to reinvest 20% of our profits made in Least Developed Countries back into infrastructure projects to help improve healthcare in the developing world.
Corporate responsibility is about how we achieve our goals and implement our business strategy. We aim to operate in a way that reflects our values and to connect business decisions to ethical, social and environmental concerns. The CR Report is just another acknowledgment that we can do well by doing good.